Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies

Next Previous
Trial Profile

A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; OR 2805 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Cancer; Carcinoma; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Malignant melanoma; Non-small cell lung cancer; Sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors OncoResponse

Most Recent Events

  • 24 Jan 2024 This trial has been Completed in France, According to European Clinical trials database record.
  • 30 Sep 2022 Planned number of patients changed from 130 to 172.
  • 07 Jun 2022 According to trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology, this study enrolling patients at sites in the United States with planned expansion within the US and to Europe.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top